8-K Announcements
6Material company update
Jun 4, 2026·SEC
Material company update
May 27, 2026·SEC
Material company update
Apr 24, 2026·SEC
Medicus Pharma Ltd.(MDCXW)Earnings, Financials & Key Ratios
MDCXW•NASDAQ
$0.49
Price updated Jun 27, 2026
AboutMedicus Pharma Ltd. is a clinical-stage biotech company focused on accelerating the development of novel therapeutic assets. Their lead subsidiary, SkinJect Inc., is developing a non-invasive treatment for basal cell carcinoma using a dissolvable microneedle patch to deliver chemotherapeutic agents directly to tumor cells.Show more
- Revenue$0
- EBITDA-$18M-64.5%
- Net Income-$25M-127.4%
- EPS (Diluted)-1.96-69.0%
- ROE-1599.39%-204.4%
MDCXW Price & Volume
Medicus Pharma Ltd. (MDCXW) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Threaten Solvency and Equity
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding dependency
Key Thesis Takeaways
- Medicus Pharma remains a high-risk, pre-revenue biotechnology entity entirely dependent on the successful progression of its SkinJect clinical program.
- The firm's reliance on debt financing to sustain R&D expenditures, which peaked at $10.4 million in 2025Q3, creates significant pressure on its fragile capital structure.
- Investors should monitor the company's ability to manage its narrowing liquidity buffer, as the current cash position of $6.4 million as of 2026Q1 provides a limited runway for ongoing operations.
Verdict Logic
the company's rapid erosion of shareholder value, evidenced by the equity position swinging to a deficit of $49.3 thousand in 2025Q4, suggests an unsustainable path for long-term capital appreciation.
MDCXW Growth Metrics
Medicus Pharma Ltd. (MDCXW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-155.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-48.65%
Return on Capital
10 Years-662.46%
5 Years-662.46%
3 Years-662.46%
Last Year-1059.55%
Peers Comparison
Key metrics vs top competitors for Medicus Pharma Ltd. (MDCXW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.50 | $10.91M | -0.25 | — | — | -1599.39% | — | |
| $21.31 | $1.88B | -6.48 | 627.84% | -112.01% | -256.66% | — | |
| $55.83 | $8.55B | 20.16 | 87.32% | 65.95% | 87.36% | — | |
| $13.49 | $1.13B | -25.45 | — | — | -38.92% | — | |
| $38.85 | $7.98B | -14.03 | — | — | -68.16% | — | |
| $63.65 | $1.24B | -6.54 | -43.89% | -284.18% | -87% | — |
Compare MDCXW vs Peers
Medicus Pharma Ltd. (MDCXW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MDCXW SEC Filings & Documents
Medicus Pharma Ltd. (MDCXW) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when MDCXW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MDCXW Frequently Asked Questions
Medicus Pharma Ltd. (MDCXW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is MDCXW profitable?
Medicus Pharma Ltd. (MDCXW) reported a net loss of $36.9M for fiscal year 2025.
Dividend & Returns
What is MDCXW's return on equity?
Medicus Pharma Ltd. (MDCXW) has a return on equity (ROE) of -1599.4%. Negative ROE indicates the company is unprofitable.
What is Medicus Pharma Ltd.'s free cash flow?
Medicus Pharma Ltd. (MDCXW) had negative free cash flow of $23.4M in fiscal year 2025, likely due to heavy capital investments.